GLOW Legal Status, FDA 503A Category, and Compounding Access

GLOW legal status: where the FDA record stands and where it is moving

The most forward-looking fact about GLOW legal status is also a hedged one: access to the blend's peptides is under active FDA review and may expand in 2026. The U.S. Food and Drug Administration has scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23-24, 2026 to discuss BPC-157 and TB-500 — two of GLOW's three constituents — as candidates for inclusion on the 503A bulks list ^[14]. That is real momentum: substances do not reach a PCAC agenda without being formally under evaluation.

Momentum is not a decision. A PCAC discussion is advisory; it is a step in FDA's evaluation, not a final listing decision, and no outcome should be assumed or dated ^[13][14]. As of the most recent confirmable FDA action, the present-tense status is restrictive. GHK-Cu (for injectable routes), BPC-157, and the thymosin beta-4 fragment marketed as TB-500 each sit in FDA's 503A "Category 2" — bulk drug substances FDA has identified as potentially presenting significant safety risks — effective with the September 29, 2023 update to the nominated-substances list ^[12]. Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1, which means routine pharmacy compounding access is currently restricted ^[12][13]. The honest reading: the door is being reviewed, and today it is mostly closed.

What FDA 503A Category 2 means for these peptides

Under the Federal Food, Drug, and Cosmetic Act, drug compounding runs through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally under a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight ^[13]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list; substances not yet listed are evaluated by FDA through a public nomination process informed by PCAC ^[13].

FDA's interim policy sorted nominated substances into categories. Category 1 substances may be eligible for the bulks list and are covered by FDA's enforcement-discretion policy while under evaluation. Category 2 substances are those FDA identified as raising significant safety risks; they are not afforded that discretion, and FDA has stated it would consider taking action against a compounder using one ^[12][13]. For GLOW's constituents, FDA cited concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization ^[12]. On January 7, 2025, FDA finalized a revised policy under which it no longer places newly nominated substances into these numbered categories; existing Category 1 substances retain the interim enforcement discretion, while substances in Category 2 do not regain it even with updated nominations ^[13]. None of GLOW's three peptides is an FDA-approved drug — a separate question from whether a bulk substance may be compounded.

The constituents, separated: which are on the July 2026 agenda

GLOW's three peptides do not share one regulatory line, and the blend inherits the strictest. Two of the three are on the July 23-24, 2026 PCAC agenda as substances being considered for inclusion on the 503A bulks list: BPC-157 (listed as "BPC-157 (free base)" and "BPC-157 acetate") and TB-500 (listed as "TB-500 (free base)" and "TB-500 acetate") ^[14]. Their appearance on the agenda is consistent with their evaluation being ongoing rather than resolved — under review, not reclassified ^[12][14].

GHK-Cu is the exception, and it carries a split status that must be kept separate. The copper peptide is not on the July 2026 PCAC agenda ^[14]. Its injectable form remains in Category 2 — FDA identified "GHK-Cu (for injectable routes of administration)" as potentially presenting significant safety risks, effective September 29, 2023 ^[12]. That injectable-drug status is distinct from cosmetic use: GHK-Cu labeled "Copper Tripeptide-1" is used as an ingredient in topical skincare and is regulated under cosmetics rules, which do not require FDA pre-market approval of the ingredient ^[16]. A topical copper tripeptide cream and an injectable GHK-Cu compounding substance are two different regulatory questions; this page keeps them apart. There are also unconfirmed reports circulating in 2026 of pending reclassification of some Category 2 peptides; because no completed, effective FDA action confirms them, this page does not treat any reclassification as having occurred.

How legally compounded peptide access works

Setting the blend aside, it helps to understand how legally compounded medication reaches a patient in general terms. The pathway is consistent regardless of the substance. First, a patient is evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate ^[13]. Telehealth here is simply one front-end channel for that evaluation; it does not expand which substances may be compounded and does not remove the need for a legitimate clinical relationship and a valid prescription ^[13].

If appropriate and lawful, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A compounding pharmacy (patient-specific) or, for office and batch use, sourced from an FDA-registered 503B outsourcing facility ^[13]. The decisive caveat is the ingredient-eligibility rule: a compounder may use a requested active ingredient only if it is eligible under the 503A/503B bulk-substance framework. Ingredients FDA has flagged for significant safety risks — which currently includes injectable GHK-Cu, BPC-157 and the TB-500 fragment — are not eligible for routine 503A compounding while that status stands ^[12][13]. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to supply any substance.

Is GLOW legal?

GLOW is a blend, and its components do not share one legal status. Topical Copper Tripeptide-1 is a lawful cosmetic ingredient ^[16], but injectable GHK-Cu, BPC-157 and the TB-500 fragment each sit in FDA's 503A Category 2, identified as potentially presenting significant safety risks and not within FDA's compounding enforcement-discretion policy as of the September 29, 2023 list update ^[12]. None is an FDA-approved drug, and the blend inherits the strictest constituent status.

Can you get GHK-Cu from a compounding pharmacy?

Injectable GHK-Cu is in FDA's 503A Category 2, meaning FDA identified it as potentially presenting significant safety risks and it is not covered by the enforcement-discretion policy for compounding; routine 503A access is restricted while that status stands ^[12][13]. Separately, topical Copper Tripeptide-1 is a cosmetic ingredient regulated under cosmetics rules, a different question from injectable compounding ^[16].

What is the FDA 503A status of GLOW?

GLOW has no status of its own; status applies to each bulk substance. Injectable GHK-Cu, BPC-157 and the TB-500 fragment are each in 503A Category 2, effective with FDA's September 29, 2023 update ^[12]. BPC-157 and TB-500 are on the July 23-24, 2026 PCAC agenda as candidates being considered for the 503A bulks list — a scheduled discussion under active review, not a decision or a change in current status ^[14].

Why did the FDA restrict BPC-157?

FDA placed BPC-157 in 503A Category 2 — bulk substances identified as potentially presenting significant safety risks — effective with the September 29, 2023 list update, citing concerns including potential immunogenicity for certain routes and complexities with peptide-related impurities and active-ingredient characterization ^[12]. BPC-157 is an unapproved substance with no FDA-approved therapeutic indication.